New menopause research findings presented at The Menopause Society’s annual meeting this week are reshaping how clinicians approach weight management, cognitive function, and gastrointestinal health in midlife women.
Key Takeaways
- GLP-1 and Hormone Therapy: Emerging data suggests that when paired with hormone therapy, GLP-1 medications may help menopausal women achieve sustained weight loss comparable to women in other life stages.
- ADHD and Brain Fog: While ADHD medications like Vyvanse and Strattera may improve subjective executive function, they do not appear to impact working memory or sustained attention in women experiencing brain fog.
- Gut-Brain Connection: Research indicates a bidirectional relationship between menopause-related gastrointestinal distress, such as bloating, and increased anxiety levels.
- Lifestyle Interventions: “Exercise prescriptions” and shared medical appointments are emerging as highly effective models for helping women implement critical lifestyle changes.
- Clinical Caution: Experts warn against using compounded pharmacies for GLP-1s and urge women to avoid self-diagnosing ADHD symptoms.
- Observational Data: The research, which included 2,400 women, is based on observational data, meaning outside factors could influence the weight loss outcomes.
- Muscle and Bone Mass: As fat is lost, there is a risk of losing lean muscle mass and bone mass—a risk already heightened during menopause due to declining estrogen levels. Researchers are still investigating whether this loss is more pronounced in women than in men.
- Compounded Medications: Dr. Faubion strongly advised against obtaining GLP-1s from compounded pharmacies. She noted that because these drugs are difficult to manufacture, some online pharmacies may not actually be providing semaglutide, leaving clinicians unaware of the true ingredients and potential side effects.
- Participants in shared appointments were more likely to initiate beneficial behaviors regarding exercise, sleep, stress management, and sexual function compared to those in one-on-one appointments.
- The group setting acts as a “commitment device,” where the social dynamic motivates participants to follow through on their goals.
- The extended duration allows for a more thorough exploration of complex issues that cannot be addressed in a standard appointment.
- If you are managing weight: Discuss the potential benefits of combining GLP-1 medications with hormone therapy with your clinician, but be wary of using non-regulated, compounded medications from online sources.
- If you are experiencing cognitive shifts: If “brain fog” is interfering with your life, ask your doctor for an ADHD screening tool. If you screen positive, request a referral to a mental health professional rather than relying solely on an OB-GYN.
- If you are experiencing digestive or mood changes: Recognize that bloating, gas, and anxiety may be linked. Tracking these symptoms can help your doctor identify patterns and potentially treat the underlying hormonal cause.
- If you are struggling with activity levels: Ask your physician for a formal “exercise prescription” that includes specific movements you can perform at home to reduce the barrier to entry.
- Microbiome Research: Researchers, led by Sanjana Solomon, intend to study the microbiomes of menopausal women to clarify the link between gut health and anxiety.
- Long-term GLP-1 Studies: More rigorous clinical trials are needed to determine the long-term effects of GLP-1s on bone and muscle mass in menopausal populations.
- Behavioral Economics in Medicine: Further research will likely explore how group dynamics and shared appointments can be integrated into standard clinical practice to drive long-term lifestyle changes.
- www.aarp.org
What Happened
During the annual meeting of The Menopause Society, a diverse group of researchers and medical experts presented a series of studies addressing the complex physiological and psychological shifts occurring during perimenopause and menopause. The findings spanned multiple disciplines, including endocrinology, gastroenterology, and psychiatry, providing a multifaceted view of midlife health.
Key presentations focused on the efficacy of GLP-1 medications for weight management, the distinction between ADHD and perimenopausal brain fog, the prevalence of gastrointestinal symptoms, and the potential of group-based medical models to improve patient outcomes. These findings come at a time when midlife women are increasingly seeking pharmacological and lifestyle-based solutions to manage the symptoms of hormonal fluctuations.
Why It Matters
For millions of women, the transition into menopause is marked by metabolic, cognitive, and digestive changes that can significantly impact quality of life. The data presented this week highlights a critical gap between current clinical practices and the evolving needs of this demographic.
As weight management becomes a primary concern—particularly due to the tendency for midlife weight gain to accumulate in the abdominal area—the role of GLP-1 medications is under intense scrutiny. Simultaneously, the rising rates of adult ADHD diagnoses among women necessitate a clearer understanding of how hormonal shifts might mimic or exacerbate cognitive symptoms. Furthermore, the high prevalence of gastrointestinal issues and anxiety suggests that menopause cannot be treated as a series of isolated symptoms, but rather as a systemic transition requiring integrated care.
Deep-Dive: GLP-1 Use and Metabolic Health
One of the most significant areas of discussion involved the use of GLP-1 medications, which have seen a surge in popularity for weight management. According to Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women’s Health and medical director of The Menopause Society, approximately 1 in 5 women between the ages of 50 and 64 have taken a GLP-1, representing the highest usage rate of any age group.
However, the research revealed a nuance in how these drugs affect women in different life stages. Dr. Faubion explained that women in menopause tend to lose less weight on GLP-1s than women who are premenopausal or perimenopausal. This disparity may be linked to the biological changes caused by estrogen depletion.
The Role of Hormone Therapy
Crucially, new emerging research suggests a potential synergy between hormone therapy and GLP-1s. When used in combination, GLP-1s appear to be as effective at achieving sustained weight loss in menopausal women as they are in women at other stages of life. Dr. Faubion clarified that the hormone therapy does not necessarily cause women to lose “oodles more” weight, but rather enables them to “catch up to what their peers might have lost.”
Despite these promising results, Dr. Faubion issued several important caveats:
Deep-Dive: Distinguishing ADHD from Brain Fog
As more women receive ADHD diagnoses in adulthood, clinicians are facing the challenge of distinguishing between true ADHD and the “brain fog” reported by an estimated 44% to 60% of perimenopausal women.
Jennifer Tat, the lead author of a new study from the University of Tennessee Health Science Center, noted that while the symptoms can look similar, a key differentiator is duration: perimenopausal brain fog generally resolves over time, whereas ADHD does not.
Medication Efficacy and Limitations
A review of studies presented at the meeting examined how ADHD medications might interact with these symptoms. The findings regarding two specific medications were as follows:
| Medication | Reported Impact on Women | Limitations Found |
|---|---|---|
| Vyvanse (lisdexamfetamine) | Improved subjective perception of executive functioning | No effect on working memory or sustained attention |
| Strattera (atomoxetine) | Improved subjective perception of executive functioning | No effect on working memory or sustained attention |
Tat emphasized that while these medications may help with executive function, they are not a universal fix for menopause-related cognitive shifts. She also cautioned that these medications should not be prescribed in an OB-GYN setting without proper screening. Instead, clinicians should use screening tools to identify patients who may need a referral to a psychiatrist for a structured interview.
Deep-Dive: The Gut-Brain Connection
While hot flashes are the most recognized symptom of menopause, new research highlights the significant impact of hormonal fluctuations on the digestive system and mental health.
Data from the University of Calgary, involving more than 1,800 women aged 40 to 60, found that gastrointestinal (GI) symptoms are remarkably prevalent. Specifically, excessive bloating and gas were identified as the most common menopause-related GI symptoms, with roughly 66% of women in the study scoring above the normal severity range.
Anxiety and GI Distress
There is also a documented link between these physical symptoms and mental health. The study found that nearly 20% of women reported moderate to severe anxiety during menopause, with higher levels of anxiety often occurring during perimenopause.
Sanjana Solomon, the lead author of the University of Calgary study, noted that anxiety is modestly correlated with an increase in GI symptoms. Dr. Faubion added that this creates a “disruptive bidirectional interaction,” where GI distress can trigger anxiety, and anxiety, in turn, can exacerbate gut symptoms. Future research will focus on studying the microbiomes of these women to better understand this relationship.
Deep-Dive: New Models for Lifestyle Intervention
Despite the clinical benefits of exercise and diet, many women in midlife struggle to maintain these habits. Data indicates that only 7% of midlife women routinely meet physical activity guidelines, and only 24% engage in strength training at least twice a week.
To combat this, medical professionals are advocating for “exercise prescriptions”—specific, written instructions from a doctor detailing the type, frequency, and method of activity. Dr. Amy Comander, medical director at the Mass General Cancer Center, explained that these prescriptions help overcome psychological barriers, such as the intimidation of a gym environment, by suggesting home-based exercises like planks, squats, and lunges.
The Power of Shared Medical Appointments
Beyond individual prescriptions, a new model of care is showing promise: the shared medical appointment. Unlike traditional 20-minute one-on-one consultations, these sessions involve groups of 10 to 12 people meeting for 1.5 to 2 hours.
Dr. Karen Adams, a clinical professor at Stanford University, led a study with 28 women to test this model. The results were significant:
What It Means for You
If you are navigating perimenopause or menopause, these research findings suggest several actionable steps:
Counterpoints and Open Questions
While the research presented is encouraging, several significant questions and risks remain unaddressed.
First, the reliance on observational data for GLP-1 studies means that a definitive causal link between the medication-hormone combination and weight loss has not been established. There is also the critical unknown of long-term muscle and bone density impacts. As Dr. Faubion noted, the consequences of long-term GLP-1 use—which often must continue for life to maintain efficacy—are still being studied.
Second, the use of ADHD medications for cognitive symptoms in menopause is still in the early stages of investigation. The fact that these drugs do not improve working memory or sustained attention suggests they may only be treating a subset of symptoms, potentially leaving other cognitive deficits unaddressed.
Finally, while shared medical appointments show promise, their scalability and financial feasibility for all patients remain questions that require further clinical trials.
What Happens Next
Moving forward, the scientific community is focusing on several key areas of investigation:
Frequently Asked Questions
Can GLP-1 medications help with menopause-related weight gain?
Yes, but the effectiveness may vary. Research suggests that while menopausal women may lose less weight on GLP-1s than premenopausal women, pairing the medication with hormone therapy can help menopausal women achieve weight loss results comparable to their younger peers. However, doctors warn of potential risks to muscle and bone mass.
Is menopause brain fog the same as ADHD?
Not necessarily. While both can involve difficulties with focus and executive function, perimenopausal brain fog typically resolves as hormone levels stabilize. ADHD is a chronic condition. Because the symptoms overlap, experts recommend using formal screening tools and consulting a psychiatrist for a definitive diagnosis.
How can I manage menopause-related bloating and gas?
Since GI symptoms like bloating and gas are highly prevalent (affecting roughly 66% of women in some studies), managing them often involves addressing the underlying hormonal fluctuations. Because there is a bidirectional link between gut distress and anxiety, managing stress and anxiety may also help alleviate gastrointestinal symptoms.
What is an “exercise prescription”?
An exercise prescription is a formal, written instruction from a healthcare provider that specifies exactly what kind of physical activity you should do, how often, and how to incorporate it into your routine. This can include specific movements, such as squats or planks, designed to be done at home to make exercise more accessible.
Closing
The findings from The Menopause Society’s annual meeting underscore that menopause is a complex, systemic transition
References
Featured image: Photo by cottonbro studio on Pexels
